Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug development company BiPar Sciences has announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme, the most common glioma in adults.
Subscribe to our email newsletter
BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar’s DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by investigators from the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group.
In addition to GBM, BiPar is currently enrolling BSI-201 in a randomized Phase II trial for triple-negative breast cancer and is initiating Phase II trials in uterine and BRCA-negative ovarian cancers.
Barry Sherman, BiPar’s executive vice president, said: “The scientific observations that BSI-201 crosses the blood-brain barrier and has a mechanistic basis to synergize with the standard treatment of glioblastoma multiforme (GBM) makes this a promising study. It is the promise of this approach that encouraged the leaders of NABTT to evaluate BSI-201 in patients with GBM.”